Natera INC. and University of California, San Francisco (UCSF) have entered a research agreement to analyse and study the DNA markers of kidney transplant rejection.

According to the agreement, the partners will investigate the level of donor-derived, cell-free DNA (dd-cfDNA) in hundreds of banked plasma samples collected at UCSF, using Natera’s Proprietary PCR platform and algorithms.

The agreement enables the partners to analyse whether the routine measurements of dd-cfDNA can predict the organ injury and therefore improve clinical outcomes.

Evelo Biosciences has entered a research agreement with Mayo Clinic to further develop novel immune-microbiome cancer therapies.

According to the agreement, the two partners will jointly work on isolation and characterisation of cancer-associated bacteria from patient’s samples and tumour biopsies for the development of onco-microbials to treat cancer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Attenua INC. has entered a definitive agreement to acquire oral Neuronal Nicotinic Receptor assets from Catalyst Biosciences.

Pursuant to the agreement, Attenua will pay an upfront payment of $1m and up to $105m as development, regulatory and commercial milestone payments, and royalties to Catalyst Biosciences.

The transaction enables Attenua to expand its businesses and Catalyst Bioscienes to realise additional value for a subset of the non-core assets.

"Attenua INC. has entered a definitive agreement to acquire oral Neuronal Nicotinic Receptor assets from Catalyst Biosciences."

Protagonist Therapeutics, a biotechnology company, has announced an initial public offering (IPO) of 5,835,000 of its common stock shares. The company expects to raise gross proceeds of up to $75.8m through the offering.

The company plans to invest the funds partly to advance the phase IIb clinical trials of PTG-100, to complete investigational new drug (IND) enabling studies for PTG-200 and PTG-300 and to use the remaining for working capital and general corporate purposes.

Avrobio INC. has raised $25m in a series A venture financing round, which was co-led by Atlas Venture L.P. Clarus Venture LLC, and SV Life Sciences Advisers LLP.

The company plans to use the proceeds to further develop the clinical-stage programmes for fabry disease and acute myeloid leukaemia, as well as expand its pipeline for rare diseases and solid and liquid cancers.


Image: Evelo Biosciences has entered a research agreement with Mayo Clinic. Photo: Courtesy of Nephron. 

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now